Close Menu

NEW YORK (GenomeWeb) –Tekmira Pharmaceuticals announced yesterday that it has completed its merger with privately held hepatitis B drug developer OnCore Biopharma, a deal that was overwhelming approved by the RNAi therapeutics firm's shareholders.

In January, Tekmira first disclosed that it had agreed to merge with OnCore to create a company focused on developing an oral cure for HBV. Tekmira currently has an siRNA-based HBV drug in Phase I testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.